Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1834942 · 1 trial · 1 indication
Using the Common Terminology Criteria for Adverse Events (CTCAE) scale
Maximum plasma concentration of drug after single dose
Area under the plasma concentration curve of drug from 0 to 504 hours after single dose
| Arm | Type | Description |
|---|---|---|
| Patients with Solid tumors | EXPERIMENTAL | Dose escalation with patients having solid tumors. Patients receive escalating doses of BAY1834942 intravenously for 1 hour on Day 1 of each 21-day cycle (Q3W). If the Q3W scheme does not result in sufficient exposure, the scheme is replaced with an once-weekly (QW) dosing scheme. |
| Patients with Gastric cancer | EXPERIMENTAL | Expansion with patients having gastric and/or gastroesophageal adenocarcinoma: Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part. |
| Patients with Colorectal cancer | EXPERIMENTAL | Expansion with patients having colorectal cancer: Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part. |
| Patients with Non-small-cell-lung cancer | EXPERIMENTAL | Expansion with patients having adeno Non-small-cell-lung cancer: Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part. |
| Low-dose expansion | EXPERIMENTAL | Expansion with patients having the same cancer type (gastric cancer, or colorectal cancer, or non-small-cell lung cancer) and receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part with a dose lower than the maximum tolerated dose (MTD). |
| Name | Type | Description |
|---|---|---|
| BAY1834942 | DRUG | Dose escalation: Sequential dose levels . Dose expansion (except for low-dose expansion): With maximum tolerated dose (MTD) identified in dose escalation part. |
Inclusion Criteria: * Male or female patients aged ≥ 18 years * Patients with histologically confirmed advanced/ metastatic solid tumors: Dose escalation: solid tumor types with a expression of CEACAM6 (gastric/ GEJ cancer, esophageal cancer, NSCLC, CRC, pancreatic cancer, cervical cancer, breast c...
BAY1834942 is an investigational small molecule being developed for the treatment of advanced CEACAM6-expressing solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BAY1834942 is a small molecule designed to target CEACAM6, a protein expressed on the surface of certain solid tumors. By interacting with CEACAM6, the drug aims to interfere with tumor cell processes, though the exact mechanism is not fully detailed in available information.
BAY1834942 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded on the OTC market under the ticker symbol BAYRY.
BAY1834942 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug remains investigational, meaning it has not yet received regulatory approval for any use.
BAY1834942 has one completed Phase 1 trial, NCT03596372, titled 'Study of BAY1834942 in Patients With Solid Tumors.' The trial enrolled 30 participants with advanced CEACAM6-expressing solid tumors and was conducted in the United States, Canada, and Singapore.
No alternative names for BAY1834942 have been identified. It is a distinct investigational compound developed by Bayer AG.